Quantitative analysis of a panel of gene expression in prostate cancer—with emphasis on NPY expression analysis
暂无分享,去创建一个
S. Srivastava | G. Petrovics | L. Ravindranath | B. Furusato | Shiv Srivastava | Bungo Furusato | Gyorgy Petrovics | Lakshmi Ravindranath | Ai-jun Liu | Yong-mei Chen | Vasanta Srikantan | David G. Mcleod | Aijun Liu | V. Srikantan | yongquan chen | D. Mcleod | David G. Mcleod
[1] B. Loftus,et al. Heterogeneous expression of α‐methylacyl‐CoA racemase in prostatic cancer correlates with Gleason score , 2007, Histopathology.
[2] J. Squire,et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome , 2007, British Journal of Cancer.
[3] H. Razvi,et al. Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue. , 2006, The Canadian journal of urology.
[4] E. Lander,et al. Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.
[5] Gordon Broderick,et al. Gene Expression Correlates of Unexplained Fatigue , 2006, Pharmacogenomics.
[6] J C Reubi,et al. Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. , 2001, Cancer research.
[7] O. Dietze,et al. Vasoactive intestinal polypeptide (VIP) and neuropeptide tyrosine (NPY) in prostate carcinoma. , 1997, European journal of cancer.
[8] S. Said. Vasoactive Intestinal Polypeptide (VIP) in Asthma a , 1991, Annals of the New York Academy of Sciences.
[9] R. Montironi,et al. Carcinoma of the prostate: inherited susceptibility, somatic gene defects and androgen receptors , 2004, Virchows Archiv.
[10] J. Kench,et al. Aberrant Neuropeptide Y and Macrophage Inhibitory Cytokine-1 Expression Are Early Events in Prostate Cancer Development and Are Associated with Poor Prognosis , 2006, Cancer Epidemiology Biomarkers & Prevention.
[11] A. D'Amico,et al. Combined-modality staging for localized adenocarcinoma of the prostate. , 2001, Oncology.
[12] A. Ziaee,et al. Role of PTEN gene in progression of prostate cancer. , 2007, Urology journal.
[13] Beatrice Gralton,et al. Washington DC - USA , 2008 .
[14] P. Magni,et al. Modulatory actions of neuropeptide Y on prostate cancer growth: role of MAP kinase/ERK 1/2 activation. , 2007, Advances in experimental medicine and biology.
[15] C. Cavadas,et al. Neuropeptide Y and its receptors as potential therapeutic drug targets. , 2002, Clinica chimica acta; international journal of clinical chemistry.
[16] Arul M Chinnaiyan,et al. Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. , 2003, Urology.
[17] Paolo Magni,et al. Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells. , 2006, Endocrinology.
[18] D. Bostwick,et al. Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. , 2007, Pathology.
[19] H. Jörnvall,et al. Limited neuropeptide Y precursor processing in unfavourable metastatic neuroblastoma tumours , 2000, British Journal of Cancer.
[20] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[21] R. Fahlbusch,et al. Gene expression of adrenomedullin, leptin, their receptors and neuropeptide Y in hormone‐secreting and non‐functioning pituitary adenomas, meningiomas and malignant intracranial tumours in humans , 2001, Neuropathology and applied neurobiology.
[22] R. Vessella,et al. Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.